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Abstract
Background:  Trastuzumab is a monoclonal antibody selectively directed against Her2 and
approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed
mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by
triggering FcγRIII on natural killer (NK) cells. This study addresses the correlation between overall
NK function and trastuzumab's clinical activity.
Subjects and methods: Clinical and immunological responses were assessed in 26 patients
receiving trastuzumab monotherapy as maintenance management after chemotherapy (8 mg/kg
load and then standard doses of 6 mg/kg every 3 weeks). Cytotoxic activity against the MHC class
I-negative standard NK target K562 cell line and HER2-specific ADCC against a trastuzumab-
coated Her2-positive SKBR3 cell line were assessed in peripheral blood mononuclear cells (PBMC)
harvested after the first standard dose. After six months, seventeen patients were scored as
responders and nine as non-responders according to the RECIST criteria, while Progression-Free
Survival (PFS) was calculated during a 12 months follow-up.
Results: The responders had significantly higher levels of both NK and ADCC activities (p < 0.05)
that were not different from those of eleven normal controls. The NK activity of the non-
responders was significantly (p < 0.05) lower than that of the normal controls. At twelve months,
there was a marked correlation between PFS and NK activity only. PFS was significantly longer in
patients with high levels of NK activity, whereas its pattern was unrelated to high or low ADCC
activity.
Conclusion: One of the mechanisms of action of trastuzumab is NK cell-mediated ADCC lysis of
the Her2-positve target cell. We show here that its potency is correlated with the short-term
response to treatment, whereas longer protection against tumor expansion seems to be mediated
by pure NK activity.
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Background
Breast cancer is the second most common cancer in the
world (after lung cancer), and a major cause of cancer-
related death in women [1].
Human Epidermal Growth Factor Receptor 2 (Her2), a
member of the ErbB family that plays an important role in
promoting oncogenic transformation and tumour growth
[2] is overexpressed in 20–30% of patients [3,4]. This
overexpression correlates with poor prognosis, including
high risk of recurrence, metastases and reduced overall
survival [2,5,6].
Trastuzumab is a humanised monoclonal antibody that
selectively targets Her2. Its use is approved for the treat-
ment of women with Her2-overexpressing breast cancer,
as determined by an accurate and validated assay [7-9].
Enhancement of Her2 degradation, inhibition of cell cycle
progression via inhibition of the mitogen-activated pro-
tein kinase pathway and suppression of antiapoptotic
phosphatylinositol 3-kinase and Akt pathways have been
shown to follow its binding to Her2-overexpressing cells
[10-15]. However, only 25–30% [10] or 18% [15] of
patients with Her2 over-expression respond to treatment.
There is thus a need to find predictive response markers in
order to select patients likely to benefit from this treat-
ment and spare others its adverse effects [15]. Reliable
markers may emerge from evaluation of all the players
involved in trastuzumab-mediated tumor regression.
Both cytostatic and cytolytic mechanisms account for the
clinical effect of trastuzumab. Her2-related cytotoxicity
includes complement-mediated and antibody-dependent
cellular cytotoxicity (ADCC) mediated by FcγRIII [16-22].
Cell subsets that mediate ADCC include neutrophils,
monocytes, and natural killer (NK) cells. NK cells are cyto-
toxic in two ways. First, they spontaneously lyse virus-
infected or transformed cells in the absence of prior sensi-
tization. Since this activity is under the dominant control
of inhibitory receptors (iNKRs) that bind class I human
leukocyte antigen (HLA), it is thought to be only effective
against tumor cells that lack MHC class I or present a
dominant-activating ligand. Second, NK cells recognize
and kill antibody-coated target cells during ADCC [19-
23]. Increased number of NK cells at the tumor site after
trastuzumab and a correlation between NK tumor infiltra-
tion and clinical response [22] are convincing evidence of
their participation in tumor clearance. The present study
addresses the significance of NK cells in the mechanism of
action of trastuzumab by comparing their functional state
and the clinical outcome in metastatic breast cancer
patients.
Methods
Patients
Twenty-six metastatic breast cancer patients (Table 1)
received trastuzumab as a single agent after chemotherapy
in the form of an 8 mg/kg load followed by 6 mg/kg
standard doses every 3 weeks for 1 year, or until evidence
of disease progression or unacceptable toxicity. NK and
ADCC activities were assessed in occasion of the first
standard dose. Clinical response was evaluated radiologi-
cally and classified according to the RECIST criteria.
Patients experiencing CR, PR and SD were considered
responders, as opposed to PD patients who were consid-
ered non-responders (Table 1).
Cytokines and Antibodies
Recombinant human IL-2 was purchased from Chiron
(Milan, Italy). The humanized anti-Her2 MoAb trastuzu-
mab was kindly provided by Genentech Inc. (San Fran-
cisco, California, USA).
Table 1: Characteristics of patients
Patient # Type of mts No. of mts Response
999 Visceral1 > 3 DP
1025 Visceral < 3 CR
1080 Visceral > 3 DP
1081 Visceral < 3 DP
1083 Visceral > 3 PR
1095 Visceral < 3 CR
1125 Visceral > 3 DP
1126 Visceral < 3 SD
1102 Non-visceral2 > 3 CR
1103 Non-visceral < 3 SD
1110 Non-visceral < 3 CR
1121 Non-visceral > 3 DP
1123 Non-visceral < 3 SD
1124 Non-visceral < 3 CR
1019 Mixed3 > 3 PR
1020 Mixed > 3 SD
1021 Mixed > 3 PR
1026 Mixed > 3 DP
1082 Mixed > 3 DP
1104 Mixed > 3 PR
1105 Mixed > 3 SD
1116 Mixed > 3 DP
1270 Visceral < 3 RC
1276 Mixed > 3 PR
1279 Non-visceral < 3 PR
1280 Visceral > 3 PD
1Visceral mts: liver, lungs, CNS
2Non-visceral metastases (mts): bones, locoregional lymph nodes, 
skin
3Mixed: visceral and non-visceral
DP: disease progression; CR: complete remission; PR: partial 
remission; SD: stable disease.Journal of Translational Medicine 2008, 6:25 http://www.translational-medicine.com/content/6/1/25
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Cell lines
The human breast adenocarcinoma lines SKBR3 and
MCF7 were grown as adherent cells and used as Her2-pos-
itive and Her2-negative lines, respectively. The non-adher-
ent leukaemia cell line K562 [24] was used as an MHC
class I-negative, NK susceptible target. Its NK susceptibil-
ity was tested in pilot and concurrent experiments against
the standard NK-resistant DAUDI cell line. Culture
medium was RPMI 1640 (Life Technologies Ltd, Paisley,
Scotland, UK) supplemented with 20% (SKBR3 and
MCF7) or 10% (K562) heat inactivated fetal calf serum
(FCS), 1% L-glutamine, 1% penicillin and streptomycin
(Sigma-Aldrich, Milan, Italy).
Isolation of PBMC
Peripheral blood mononuclear cells (PBMC) obtained
after Ficoll-Hypaque density centrifugation of venous
blood of patients and age-matched normal donors were
washed in RPMI 1640 supplemented with 5 mM EDTA
(Sigma-Aldrich) and 2% heat inactivated FCS and resus-
pended in RPMI 10% FCS.
ADCC and NK cytotoxicities
To evaluate ADCC, the SKBR3 and MCF7 breast cancer
cell lines were incubated with 10 μg/ml trastuzumab at
4°C for 30 minutes. The mAb excess was removed by
washing at 4°C to prevent capping and Ag-Ab complexes
endocytosis. The cells were used as targets in a 51Cr release
cytotoxicity assay, where the mAb uncoated K562 line was
used to evaluate NK activity. This assay was conducted as
previously described [25]. Briefly, targets cells were incu-
bated with 100 μCi Na2 
51CrO4(Perkin Elmer, Milan,
Italy), for 1 h, washed and added (5 × 103/well of a 96-
well V-bottomed plate) to different numbers of effector
cells to obtain decreasing effector to target (E:T) ratios
(50:1, 25:1 and 12:1), or cultured with medium alone or
TritonX-100. Plates were incubated at 37°C for 4 h, and
the supernatant (100 μl) was harvested for quantification
in a γ-counter. Triplicate wells were set up for each E:T
dilution and the percentage of lysis was calculated accord-
ing to the formula: (experimental release – spontaneous
release)/(maximal release – spontaneous release) × 100,
where experimental release represents the mean counts
per minute (cpm) for the target cells in the presence of
effector cells, spontaneous release represents the mean
cpm for target cells incubated without effector cells, and
maximal release represents the mean cpm for target cells
incubated with TritonX-100. Experiments with spontane-
ous releases higher than 10% (for the non-adherent cell
line K562) or 20% (for the adherent cell lines SKBR3 and
MCF7) were not considered.
Statistics
Responder and non-responder groups were compared
using unpaired Student's t-test and Welch's t-test for une-
qual variance. Receiver operating characteristic (ROC)
curve analysis was performed to detect optimal cut-off
points of NK and ADCC to evaluate the clinical response
at six months. For Progression-Free Survival (PFS) analy-
sis, Kaplan-Meier curves were produced and compared
with Log-Rank tests. The statistical package STATA 9.2 was
used for all statistical tests and a two-tailed p-value of less
than .05 was considered significant.
Results
Expression of Her2 on SKBR3 and MCF7 cell lines
Since conflicting assessment have been made of the
expression of Her2 on MCF7 cells [17,19,22], we have
unequivocally stated the Her2 expression of our two lines.
Results show that the SKBR3 is highly Her2-positive,
whereas the MCF7 line is substantially Her2-negative (Fig.
1).
In vitro cytotoxicity of NK targets and breast tumor targets 
by patient's PBMC correlates with their clinical response 
at six months
Patients undergoing trastuzumab monotherapy after tras-
tuzumab-chemotherapy association were tested for NK
activity against the NK target K562 and for ADCC activity
against the trastuzumab-coated Her2-positive cell line
SKBR3 in a 51Cr release assay. The Her2-negative cell line
MCF7 was employed as a negative control for the ADCC.
After six months seventeen patients were classified as
responders (CR, PR and SD) and nine as non-responders
(PD) according to the RECIST criteria (Table 1). Both NK
(Fig. 2A). and ADCC (Fig. 2B). activities were two-fold
higher in the responders. This difference was significant at
all three E:T ratios. As expected, ADCC against the Her2-
negative cell line MCF7 was much lower than that against
the SKBR3 cell line (Fig. 2C). Furthermore, the NK and
ADCC activities of responders were not different from
those of eleven normal controls (Fig 3A and 3B), whereas
the NK activity of the non-responders was significantly
lower (Fig. 4A) and their ADCC activity (Fig. 4B) was
clearly lower than normal, though only significant at the
highest E:T ratio.
Correlation between NK and ADCC activities and PFS
The Kaplan-Meier PFS curve showed that 25% and 50% of
patients were in PD at 6 and 12 months respectively (Fig.
5). ROC analysis was used to provide an optimal cut-off
for discrimination of high an low NK and ADCC activities
at the three E:T ratios and stratified PFS curves were cre-
ated. Results show that patients with higher levels of NK
activity are significantly less likely to relapse within twelve
months (Log-Rank test p-values 0.168, 0.033 an 0.024 at
the 50:1, 25:1 and 12:1 E:T ratios respectively (Fig. 6). By
contrast, the advantage of a high ADCC activity is only
evident at six months. At twelve months, the percentage ofJournal of Translational Medicine 2008, 6:25 http://www.translational-medicine.com/content/6/1/25
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relapsing patients with either a high or a low initial ADCC
activity is 50% (Fig. 7).
Discussion
Patients with Her2-overexpressing breast tumors nor-
mally become resistant to trastuzumab after one year.
Hence, in addition to protein overexpression and gene
amplification of Her2, other predictive response markers
are needed to optimize its clinical use.
Since NK cell-mediated killing of the mAb-coated Her2-
positive autologous tumor is part of the mechanism of
action of trastuzumab, the functional state of NK cells
may also critically influence the clinical outcome. We
have therefore correlated this pretreatment biomarker
with clinical response to trastuzumab after 6 months and
12 months. Results show that the short-term response
rests on efficient NK and ADCC functions, whereas the
long-term response is correlated with high NK function,
but is independent of the ADCC profile.
In vitro studies [17,19] have demonstrated that NK cells
kill trastuzumab-coated Her2-overexpressing cells via a
FcγRIII receptor-mediated ADCC mechanism. This activ-
ity is very likely to recapitulate the destiny of the host
tumor cells upon trastuzumab administration. Indeed,
the significance of antibody-mediated killing in the clini-
cal effect of humanized mAbs has been confirmed by clin-
ical data [26]. In particular, experimental [17,19] and
clinical [21,22] data point to the importance of the FcγR
in trastuzumab's clinical efficiency PBMC from trastuzu-
mab-treated patients displayed cytopathic activity in vitro
against Her2-overexpressing cells. ADCC activity was
more pronounced in tumours demonstrating a good
response [21]. Moreover, increased infiltration of NK cells
has been observed at the tumor site after trastuzumab
[22]. However, evaluation of ADCC in metastatic breast
cancer patients treated with a combination of trastuzu-
mab and interleukin-2 (IL-2) [20,26] or IL-12 [27] (two
activators of NK cells) did not confirm a correlation with
clinical responses.
Our data show that patients with normal levels of both
NK and ADCC activities respond more favourably to tras-
tuzumab after a six month observation.
The ADCC performance status seems to depend on indi-
vidual-related characteristics [28] such as FcγR polymorf-
isms [28,29], as well as the relative frequency of FcγR
(CD16+)CD3+ vs CD56+CD3- NK subpopulations [[29]
and our unpublished data], rather than on the individual
trastuzumab pharmacokinetics [29].
Different Her2 expression of the ADCC target cell lines Figure 1
Different Her2 expression of the ADCC target cell lines. The human breast carcinoma cell lines MCF7 and SKBR3 
were stained with the humanized anti-Her2 MoAb trastuzumab (Genentech Inc. San Francisco, California, USA) and analysed 
by flow cytometry.Journal of Translational Medicine 2008, 6:25 http://www.translational-medicine.com/content/6/1/25
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NK and ADCC profile of patients classified as responders and non-responders after a six-month trastuzumab regimen Figure 2
NK and ADCC profile of patients classified as responders and non-responders after a six-month trastuzumab 
regimen. NK and ADCC activities of PBMC were tested at the start of trastuzumab therapy against the target K562 cell line 
(A) and the trastuzumab-coated Her2-positive cell line SKBR3 (B) in a 51Cr release assay. The trastuzumab-coated Her2-nega-
tive cell line MCF7 (C) was used as control for ADCC. Values of NK (A) and ADCC (B) cytotoxicity were always significantly 
higher in responders at all three E:T ratios.
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Responders have normal NK and ADCC activities Figure 3
Responders have normal  NK and ADCC activities. NK and ADCC activities were assessed as described in legend to 
Fig. 2. Values (A and B) were not significantly different in responders compared to 11 normal donors at all three E:T ratios. As 
expected, negligible ADCC activity was found both in patients and normal donors against the Her2-negative cell line MCF7 (C).
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Non-responder patients have defective Figure 4
Non-responder patients have defective NK activity. NK and ADCC activities were assessed as described in legend to 
Fig. 2. Values of NK activity (A) were significantly lower in patients compared to normal donors at three E:T ratios. ADCC 
activity (B) was significantly lower in patients only at the highest E:T ratio. As expected, negligible ADCC activity was found 
both in patients and normal donors against the Her2-negative cell line MCF7 (C).
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Whatever the mechanisms that determine an effective
ADCC response in trastuzumab- responsive patients, this
was confined in our study to the early observation period.
Longer evaluation of the response to trastuzumab, in
terms of progression-free survival after twelve months
showed a strong correlation with the levels of NK activity
only. By this time 75% of patients with low NK activity
had relapsed, whereas the same percentage of those with
high NK activity were still progression-free. By contrast,
50% of patients who had progressed after twelve months
could not been distinguished through their ability to per-
form ADCC in vitro. This suggests that NK cells can pro-
tect against breast cancer progression in an antibody-
independent fashion, a likely mechanism being targeting
of immunoedited MHC class I defective tumor cells [30].
Taken as a whole, our data show that the efficiency of the
NK system may be a hallmark of responsiveness to trastu-
zumab and suggest that breast cancer patients eligible for
its administration may benefit from enhancement of this
system in vivo. This includes combination therapy with
trastuzumab and immunomodulatory agents or construc-
tion of bispecific antibodies targeting HER2 and CD16
[31] The first approach seems the more feasible. The fact
that in vivo NK cell expansion and increased in vitro
ADCC by IL-2 [20] or IL-12 [26,27] did not result in evi-
dent clinical benefits may merely mean that optimal com-
bination of NK stimulators has still be found. A NK
stimulation threshold, represented by a combination of
IL-2 and IL-12 activates both the ADCC function and
release of the antitumor cytokines and chemokines and is
prone to be applied to clinical models [32]. IL-21 is also a
promising NK stimulator, since it enhanced the effects of
cetuximab in a murine tumor model and the human NK
cell response to Ab-coated targets [33]. Once the mecha-
nisms of ADCC function and the populations involved
are characterized adoptive transfer of ex-vivo expanded
purified ADCC effectors could be envisaged.
Time to tumor progression is correlated with the NK activity Figure 6
Time to tumor progression is correlated with the NK activity. A cut-off of 5%. 3% and 2% cytotoxicity was chosen to 
discriminate between high and low NK levels at the three E:T ratios of 50:1, 25:1 and 12:1 respectively and a stratified PFS 
curve was created from these values. The figure shows that higher NK values are significantly (Log-Rank test p values) corre-
lated with longer time to tumor progression.
Global time to tumor progression at twelve months Figure 5
Global time to tumor progression at twelve months. 
The Kaplan-Meier PFS curve shows that the percentage of 
progression-free patients is 75% at six months from start of 
Trastuzumab therapy and declines to 50% at twelve months.






	



	









ļ

	





	





            


Journal of Translational Medicine 2008, 6:25 http://www.translational-medicine.com/content/6/1/25
Page 9 of 10
(page number not for citation purposes)
Conclusion
Our finding that only patients who respond to trastuzu-
mab after a six month observation have normal levels of
NK and ADCC activities point to an important contribu-
tion of the host NK competence to the clinical response.
The observation that longer (12 months) protection
against tumor expansion is only associated with classical
NK activity suggests that NK-associated mechanisms other
than ADCC. are involved in long-term trastuzumab activ-
ity. A better prediction of trastuzumab response in indi-
vidual patients may derive from the understanding of
these mechanisms.
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NK: Natural Killer; ADCC: Antibody Dependent Cell
Cytotoxicity; PFS: Progression-Free Survival.
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